A new study of Antibe Therapeutics’ (OTCQB:ATBPF; TSX-V:ATE) ATB-346 drug candidate has shown promising results in the chemoprevention and treatment of melanoma in mice.
The article was published online in the September issue of the peer-reviewed journal, Pharmacological Research. It can be viewed here.
"Although we remain focused on our ongoing human studies to advance ATB-346 as a treatment for pain and inflammation, we have compelling data from studies of colon cancer and now melanoma," John Wallace, CSO of Antibe, said in a statement. "We are encouraged by these preliminary data and plan to continue this research in support of the potential advancement of ATB-346 into selected cancer indications."
In the study, treatment with naproxen had a modest beneficial effect, reducing tumour volume by 23% and tumour weight by 20%. On the other hand, treatment with an equivalent dose of ATB-346 was three times more effective, reducing tumour volume by 69% and tumour weight by 61%. Mechanistic studies also confirmed that ATB-346 was more effective in promoting death of cancer cells, or apoptosis.